Archives
-
YAP–NF-κB–NLRP3 Axis in Ulcerative Colitis
2026-10-08
A 2026 Life Sciences study links NF-κB p65 activation to LATS1-dependent YAP inactivation, reduced repression of NLRP3, and enhanced GSDMD-associated pyroptosis in ulcerative colitis models. Its combination of patient observations, epithelial-cell experiments, transcriptional analysis, and genetic mouse evidence supports a mechanistic model while leaving important questions about human applicability and therapeutic translation.
-
Phosphatase Inhibitor Cocktail 1 in Cardiac Signaling
2026-10-08
This source-grounded overview explains how phosphatase inhibition relates conceptually to protein phosphorylation preservation and cardiac signaling research. It distinguishes the supplier’s description of Phosphatase Inhibitor Cocktail 1 from the findings of a 2025 study on myeloid S100A8/A9 in pressure-overload heart failure, while outlining evidence strength, applicability limits, and unresolved questions.
-
Nirmatrelvir: Reading 3CLpro Evidence
2026-10-07
Nirmatrelvir (PF-07321332) provides a mechanistic benchmark for interpreting SARS-CoV-2 3CLpro research. This evidence-centered guide connects coronavirus polyprotein processing, computational findings, product characterization, and the limits of translation without overstating what docking studies can prove.
-
Prestained Protein Marker: Documented Product Overview
2026-10-07
A source-limited overview of APExBIO’s triple-color, EDTA-free protein marker, covering its documented identity, conceptual scope, and evidence limitations.
-
DED Assembly and Death-Receptor Signaling
2026-10-06
Yang et al. resolve the architecture of human FADD–procaspase-8–cFLIP complexes using X-ray crystallography and cryo-EM, addressing a major gap in death-effector domain biology. Their findings explain how complex assembly can permit limited caspase-8 activation while restraining apoptotic and necroptotic signaling, providing a structural framework for interpreting cell-death research.
-
AEBSF.HCl: Evidence, Applications, and Limitations
2026-10-06
AEBSF.HCl is a broad-spectrum irreversible serine protease inhibitor with reported applications in protease biology, APP processing, and cell-death research. This overview compares supplier-reported findings with a peer-reviewed necroptosis study and explains why AEBSF.HCl should not be assumed to inhibit lysosomal cathepsin B or reproduce that study’s mechanism.
-
Saquinavir Beyond Potency: Membrane Context in Translation
2026-10-05
Saquinavir is best understood not only as an HIV protease inhibitor, but also as a translational research probe whose target activity must be interpreted alongside membrane partitioning, permeability, and assay context. This thought-leadership article connects the compound’s viral mechanism with findings from a 2024 comparison of IAM liquid chromatography and liposome electrokinetic capillary chromatography, while defining the boundaries between physicochemical modeling, antiviral evidence, and clinical relevance.
-
HOXC8, Caspase-1, and Pyroptosis in NSCLC
2026-10-04
A 2025 Cell Death and Disease study identifies HOXC8 as a transcriptional suppressor of CASP1 that protects non-small cell lung cancer cells from pyroptotic death. Its evidence connects HOXC8 to HDAC1/2 recruitment at the CASP1 promoter and suggests that disrupting this axis may have therapeutic relevance, although the findings remain preclinical and context-dependent.
-
Betaine Hydrochloride: Evidence, Uses and Limits
2026-10-03
Betaine hydrochloride is a research reagent with potential value as a defined chemical variable in biochemical, enzymatic, cellular and molecular biology studies. However, the supplied esophageal cancer study evaluates oridonin rather than betaine hydrochloride, so its anti-inflammatory and anticancer findings cannot be transferred to betaine hydrochloride without direct evidence.
-
Prestained Protein Marker for UV-Stress Assays
2026-10-02
Use a Triple color protein ladder to connect UV-stress biology with reliable gel and membrane readouts. This workflow emphasizes transfer control, phosphoprotein compatibility, and practical troubleshooting for ZAK- and GCN2-focused Western blots.
-
Z-VAD-FMK Workflow for Apoptosis Research
2026-10-01
Build cleaner apoptosis experiments with a cell-permeable, irreversible pan-caspase inhibitor that separates caspase-dependent death from inflammatory or caspase-independent outcomes. This workflow connects THP-1 and Jurkat T-cell assays with a practical strategy for investigating TNF-associated cell death in OTULIN-related pyoderma gangrenosum models.
-
TPPU: Selective Soluble Epoxide Hydrolase Inhibitor
2026-10-01
TPPU is a potent, selective soluble epoxide hydrolase inhibitor with nanomolar activity against human and mouse sEH. It is a research-use compound for studying fatty acid epoxide signaling, inflammatory pain models, and emerging sEH–Nrf2 biology.
-
Phosphatase Inhibitor Cocktail 3 for Phosphoproteins
2026-09-30
Build more reliable phosphoprotein workflows by adding a broad-spectrum inhibitor at the lysis stage, where dephosphorylation can distort signaling results. This guide connects practical sample handling with an oxygen-glucose deprivation model of neuronal ferroptosis and shows when a concentrated DMSO formulation is advantageous.
-
Prestained Protein Marker for Cell-Free Translation
2026-09-30
Use a Triple color protein ladder to connect fractionated human cell-free translation experiments with clear gel and blot quality control. The EDTA-free design supports Phosbind SDS-PAGE and fluorescent membrane imaging while providing visible landmarks for size assessment and transfer troubleshooting.
-
Calpain Inhibitor II, ALLM: From Protease to Pathway
2026-09-29
A mechanistic and translational guide to using Calpain Inhibitor II, ALLM to interrogate protease-driven apoptosis, FAK stability, and cancer biology across leukemia, lymphoma, and TNBC models.